MoonLake Immunotherapeutics (MLTX) intrinsic value & 10-year financials
MoonLake Immunotherapeutics (MLTX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $9.55
- Market cap
- $615.6M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -259.3%
- Free cash flow (FY2025)
- -$196.0M
MLTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$227.3M | -$3.53 | -$196.0M | — | -156.8% |
| FY2024 | — | -$118.9M | -$1.89 | -$117.1M | — | -90.9% |
| FY2023 | — | -$36.0M | -$0.73 | -$43.1M | — | -191.5% |
| FY2022 | — | -$50.0M | -$1.70 | -$55.9M | — | -774.7% |
| FY2021 | — | -$4.5M | — | — | — | -82.6% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MoonLake Immunotherapeutics revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MoonLake Immunotherapeutics has historically struggled to out-earn its cost of capital, averaging just -36.9% ROIC.
MoonLake Immunotherapeutics has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
MoonLake Immunotherapeutics is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.